| Literature DB >> 35890394 |
Wentao Han1,2, Haoyu Li1,2, Baihua Chen1,2.
Abstract
Spermidine, a natural polyamine, exists in almost all human tissues, exhibiting broad properties like anti-aging, autophagy induction, anti-inflammation, anti-oxidation, cell proliferation activation, and ion channel regulation. Considering that spermidine is already present in human nutrition, recent studies targeting supplementing exogenous sources of this polyamine appear feasible. The protective role of spermidine in various systems has been illuminated in the literature, while recent progress of spermidine administration in ocular diseases remains to be clarified. This study shows the current landscape of studies on spermidine and its potential to become a promising therapeutic agent to treat ocular diseases: glaucoma, optic nerve injury, age-related macular degeneration (AMD), cataracts, dry eye syndrome, and bacterial keratitis. It also has the potential to become a potent biomarker to predict keratoconus (KC), cataracts, uveitis, glaucoma, proliferative diabetic retinopathy (PDR), proliferative vitreoretinopathy (PVR), and retinopathy of prematurity (ROP). We also summarize the routes of administration and the effects of spermidine at different doses.Entities:
Keywords: biomarker; eye; ocular diseases; spermidine; therapeutic agent
Year: 2022 PMID: 35890394 PMCID: PMC9323341 DOI: 10.3390/pharmaceutics14071500
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.525
Figure 1Polyamine’s synthesis and catabolism in mammals.
A summary of altered levels of spermidine in ocular diseases.
| Diseases | Spermidine Variation | Samples | References |
|---|---|---|---|
| Glaucoma | decreased | Serum, plasma, and aqueous humor (human) | [ |
| Cataract | decreased | Lens (rabbit) | [ |
| KC | decreased | Corneal fibroblasts (human) | [ |
| Uveitis | Decreased in 48 h then increased | Aqueous humor (rabbit) | [ |
| PDR | increased | Serum, erythrocyte, and vitreous (human) | [ |
| PVR | increased | Vitreous (human) | [ |
| ROP | Decreased (first 14 days) | Retina and lens (rat) | [ |
KC: keratoconus; PDR: proliferative diabetic retinopathy; PVR: proliferative vitreoretinopathy; ROP: retinopathy of prematurity.
Figure 2Protective effects and the mechanism that spermidine exerts on ocular diseases.
A comparison between different routes and doses administration.
| Study Type | Dose (Route) | Task | Findings | References |
|---|---|---|---|---|
| in vitro | 1–30 μM (cc) | Reverse apoptosis of RPEs treated with H2O2 | Blocked the increase of intracellular Ca2+, exhibiting anti-oxidative effect. Concentrations over 20 μM were found to be toxic. | [ |
| in vitro | 10 μM (cc) | Assess RPEs migration | Promoted the migration of RPEs. | [ |
| in vitro | 10 μM (cc) | Assess its role in RPEs proliferation | Being indispensable in RPEs proliferation. | [ |
| in vitro | 10 mM (cc) | Assess cytotoxic effect of spermine and spermidine on RPE cells | 10mM spermidine caused slight RPEs shrinkage and reduced cell density; while spermine exhibited significant cytotoxicity. | [ |
| in vitro | 100 μM (cc) | Counter the effect of NMDAr inhibitor in retinal neuronal cells | Reversed the neuro-protective effect of nafamostat, | [ |
| in vitro | 100–500 μM (cc) | Mediate oxidative degeneration of RPEs | Induced RPEs death in vitro. | [ |
| in vivo | 10 μL, 30 nmol/eye (i.v.i) | Induced RPEs and photoreceptor cell degeneration in rats. | ||
| in vivo | 10 μL, 20 nmol/eye (i.v.i) | Induced reversible RPEs and photoreceptor cell degeneration in rats. | ||
| in vivo | 10 μL, 10 nmol/eye (i.v.i) | No significant harmful effects were witnessed. | ||
| in vivo | 5 µL, 50 nmol/eye (i.v.i) | Counter the effect of NMDAr inhibitor in retina | Reversed the neuro-protective effect of nafamostat, | [ |
| in vivo | 10 μL, 20 nmol/eye (i.v.i) | Establishment of PDR murine model | Contributed to the establishment of PDR murine model. | [ |
| in vivo | 10 μL, 20 pmol/eye (i.v.i) | Assess optic nerve regeneration | Promoted optic nerve regeneration after injury. | [ |
| 10 μL, 40 pmol/eye (i.v.i) | No significant effects were observed. | |||
| in vitro | 20 μM (cc) | Assess the dose and the effect of overcoming inhibition by MAG and myelin | Could effectively reverse the inhibition of MAG and myelin. | |
| 100 μM (cc) | Diminished effects. | |||
| 500 μM (cc) | No effects. | |||
| in vivo | 10 mg/kg (s.c.) | Prevent monosodium glutamate neurotoxicity in the rat retina | Prevented neurodegeneration and neurotoxicity of monosodium glutamate in retina. | [ |
| 1 mg/kg (s.c.) | No effects. | |||
| in vitro | 20 µL, 0.2/0.5% (Gutt) | Ameliorate dry eye syndrome induced by PM2.5 | Alleviated the symptom of dry eye murine model. | [ |
| in vivo | 30 mM in drinking water (p.o.) | Assess its protective role in optic neuritis and retinal neurons. | Alleviated optic neuritis and improved visual function. | [ |
| in vitro | 4 mM (cc) | Protected RGCs from H2O2 induced oxidative stress. | ||
| in vivo | 30 mM in drinking water (p.o.) | Investigate its protective role after optic nerve injury | Prevented RGCs death, suppressed retinal degeneration, and enhanced optic nerve regeneration. | [ |
| in vivo | 30 mM in drinking water (p.o.) | Investigate its protective role in normal tension glaucoma murine model | Suppressed retinal degeneration, ameliorated visual impairment, and reduced oxidative stress level in retina. | [ |
| in vitro | 100 mM (tissue incubation) | Assess its role in delaying lens opacification. | Ameliorate lens opacification induced by Ca2+. | [ |
s.c.: subcutaneous injection; p.o.: oral; i.v.i: intravitreal injection; Gutt: eye drop; cc: cell culture.